Structure Therapeutics Inc. reported a net loss of $141.2 million for fiscal 2025, a widening from the $122.5 million loss recorded in 2024. Research and development expenses rose to $225.3 million, up 108% from $108.8 million in 2024, reflecting intensified investment in its oral GLP‑1 pipeline. Cash, cash equivalents and short‑term investments totaled $1.4 billion as of December 31 2025, giving the company a runway through the end of 2028. Earnings per share for the year were –$0.49, missing the consensus estimate of –$0.35 by $0.14, while the company’s full‑year loss widened from $122.5 million in 2024 to $141.2 million in 2025.
The company’s flagship candidate, aleniglipron, delivered positive 36‑week data in its Phase 2b ACCESS study, with placebo‑adjusted weight loss of up to 15.3% and no plateau observed. The results reinforce aleniglipron’s potential as a best‑in‑class oral GLP‑1 therapy and underscore the company’s competitive advantage in the growing obesity market.
Structure Therapeutics will report 44‑week data from the ACCESS II study in the first quarter of 2026, and it plans to initiate Phase 3 trials for aleniglipron in the second half of 2026. The timing of these milestones signals a clear path toward regulatory submission and market entry, while the strong cash position supports continued development without immediate financing needs.
CEO Raymond Stevens said, “The obesity market is clearly embracing the introduction of new oral treatment options and Structure Therapeutics is well positioned to capture market share in this important therapeutic area.” He added, “In 2025, we delivered positive Phase 2b 36‑week data for aleniglipron and advanced ACCG‑2671, our first oral small‑molecule amylin receptor agonist, into the clinic. We completed a $748 million financing providing a strong financial balance sheet to continue advancing aleniglipron which has the potential to be best‑in‑class.” Stevens also noted, “The topline results presented today show that aleniglipron is differentiated and delivered clinically meaningful, competitive and dose‑dependent weight loss with a safety profile appropriate for chronic use in a disease that impacts millions of people.”
Investors welcomed the results, citing the company’s robust cash position, the promising clinical data for aleniglipron, and the clear roadmap to Phase 3 and eventual market entry. The positive reception reflects confidence in Structure Therapeutics’ strategy to capture a share of the expanding oral obesity treatment market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.